ACD/Labs is a leading provider of scientific software solutions that facilitate effective decision making and digital transformation in chemical and pharmaceutical R&D. We enable organizations to leverage harmonized analytical, structural, and molecular information—for use by chemists and data scientists alike—in a FAIR-compliant environment. Our science-centric solutions, supported by cloud-enabled technologies, automate, manage, and proliferate chemically intelligent knowledge. For decades, ACD/Labs has helped leading R&D organizations through digitalization and engineering of data for AI initiatives. As part of Revvity Signals we will continue to help create efficiencies in workflows that improve productivity and accelerate scientific innovation.

Pion supports the development of lifesaving and life-enhancing drugs by providing tools for drug developers, formulations scientists, and pharmaceutical production. For early-stage drug developers, our cutting-edge analytical technologies and services enable in vitro measurements of solubility, permeability, pKa and lipophilicity, providing essential data to improve candidate selection and formulations decisions for both oral and subcutaneous dosage forms. Later in development, high-pressure homogenizers enable particle size reduction and ensure material consistency from bench- to production-scale.

Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology. Our mission is to facilitate the efficient development of optimal medicinal products, ranging from conventional to complex formulations, by leveraging scientific excellence. We are experts in all facets of dose selection and justification, including Drug Metabolism and Pharmacokinetics (DMPK), Clinical Pharmacology, Pharmaceutical Development, IND-NDA technical authoring, and GMP manufacturing. Our comprehensive suite of services encompasses consultancy, laboratory analysis, pharmacokinetic modelling and GMP manufacturing. This expertise enables us to guide clients through the entire drug development process, from initial discovery and preclinical studies to clinical trials and regulatory approval. Our focus is on designing and developing products that exhibit superior in vivo performance, robust manufacturability, and strong commercial potential. Based in Greater Manchester, UK, our cutting-edge facilities are equipped to support the rapid design, development, evaluation, and production of innovative formulations. By enhancing the value proposition of our global clients, we contribute to the advancement of new therapies, ultimately benefiting patients worldwide.

Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.  Selvita was established in 2007 and currently employs almost 900 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Wroclaw, Poland, as well as Zagreb, Croatia. Selvita’s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK. Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs.

With more than 30 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology/toxicology (QSP/QST), and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. 

We offer #1-ranked, easy-to-use software (GastroPlus®, ADMET Predictor®, DILIsym®, NAFLDsym®, MonolixSuite®, and more) to bridge data mining and compound library screening with QSAR models, PK/PD model development, and PBPK/TK modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. Our clinical simulations and medical communications software platforms (Pro-ficiency Performance Management and Panorama) support our clients' study quality and communications through drug development, regulatory submission, approval, and commercialization. 

The Solubility Company is a trusted preclinical CRO providing physicochemical measurement services based on the proprietary SPA method. The SPA platform technology enables rapid and accurate solubility screening from less than 100 µg of solid material and from anonymous samples! The technology is universal and works with all solvent types from aqueous media to organic solvents and formulation vehicles over a broad range of temperatures.

Our service laboratories are based in Helsinki, Finland and in Quakertown, Pennsylvania. The labs are operated by a highly skilled team with more than 50 years of experience in pharmaceutical research and development.